Clinical trials recruiting for Metastatic breast cancer
131
Recruiting trials
45
US states with sites
49
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Fulvestrant | 14 |
| Trastuzumab deruxtecan | 8 |
| Capecitabine | 7 |
| Abemaciclib | 5 |
| Ribociclib | 5 |
| Sacituzumab govitecan | 5 |
| Elacestrant | 4 |
| Capivasertib | 3 |
| Endocrine therapy | 3 |
| Everolimus | 3 |
| Letrozole | 3 |
| Palazestrant | 3 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 25 |
| Florida | 23 |
| New York | 23 |
| Massachusetts | 21 |
| California | 19 |
| North Carolina | 18 |
| Tennessee | 17 |
| New Jersey | 15 |
| Illinois | 13 |
| Connecticut | 12 |
| Arizona | 11 |
| Michigan | 11 |
Top cities
Boston, Massachusetts 20New York, New York 20Nashville, Tennessee 16Houston, Texas 15New Haven, Connecticut 11San Francisco, California 9St Louis, Missouri 9Basking Ridge, New Jersey 8Chicago, Illinois 8Commack, New York 8
Self-screener
Recruiting trials
- A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
- A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
- A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- A Study of HLD-0117 in Patients With Metastatic Breast Cancer
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
- A Study of Surgery and Radiotherapy in People With Breast Cancer
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
- A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
- Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
- Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
- Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers
- CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
- Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
- Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
- Comprehensive Outcomes for After Cancer Health
- DESTINY Breast Respond HER2-(Ultra)Low Europe
- Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
- Definitive Radiation for High-Risk Spine Metastases
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
- ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
- Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
- Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
- Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
- Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
- Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
- Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
- Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
- Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
- Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
- Fast-Her: Fasting Effects on Breast Cancer Treatment
- Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
- Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- Generative AI Patient Education Module for Breast Oncology
- Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
- HER-2 B Cell Peptide Vaccine
- HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
- Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
- Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
- Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Measuring Oncological Value of Exercise and Statin
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Cancer
- Metastases Directed Therapy for Oligometastatic Breast Cancer
- Metastasis-directed Therapy for Oligometastases of Breast Cancer
- Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
- Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
- Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
- Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
- Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Related conditions
Trials recruiting for Metastatic breast cancer often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239HER2- Negative Breast Cancer 57Advanced Breast Cancer 61Hormone Receptor Positive Breast Cancer 24Prostate cancer 1234Lung cancer 2180Triple-negative breast cancer 138Locally Advanced Breast Cancer 13HER2-positive breast cancer 75Metastatic Prostate Cancer 45
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic breast cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.